focuses on identifying, evaluating, and recommending imaging techniques and biomarkers as outcome measures in rheumatology research and clinical trials. These specialized groups assess technologies such as radiography, MRI, ultrasonography, and CT scans, as well as biochemical markers detectable in blood, urine, or tissue samples. Their work ensures that reliable and valid imaging and biomarker measures are considered for inclusion in Core Outcome Sets developed for specific diseases.
Example
The Ultrasound Working Group within OMERACT exemplifies this theme. It evaluates musculoskeletal ultrasound techniques—such as scoring systems for synovitis, enthesitis, or erosions—to determine their reliability, sensitivity to change, and feasibility as outcome measures. Their research informs recommendations for including ultrasound measures in Core Outcome Sets for diseases like rheumatoid arthritis and psoriatic arthritis.